BioNTech SE (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of BioNTech SE (NASDAQ:BNTX) have received a consensus recommendation of “Moderate Buy” from the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $142.72.

A number of equities analysts have issued reports on the company. HSBC increased their target price on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Wells Fargo & Company initiated coverage on BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective for the company. BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a report on Tuesday, November 26th.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently added to or reduced their stakes in the business. Fred Alger Management LLC bought a new position in shares of BioNTech in the third quarter valued at about $59,485,000. Baillie Gifford & Co. grew its stake in BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after buying an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in BioNTech by 63.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after acquiring an additional 7,340 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in BioNTech by 123.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after acquiring an additional 74,119 shares during the period. Finally, Discovery Capital Management LLC CT acquired a new stake in BioNTech during the second quarter worth approximately $2,467,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Price Performance

Shares of BNTX opened at $111.93 on Thursday. The stock has a 50 day simple moving average of $114.75 and a 200 day simple moving average of $104.99. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a market capitalization of $26.83 billion, a PE ratio of -53.30 and a beta of 0.18.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the previous year, the firm posted $0.73 earnings per share. The business’s revenue was up 38.9% on a year-over-year basis. Sell-side analysts predict that BioNTech will post -3.71 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.